Fierce Health Payers November 19, 2021
Providers could face a 40% cut on average to their Medicare Part B drug reimbursements under legislation that gives Medicare the power to negotiate a small amount of drug prices in Parts B and D, a new analysis finds.
The analysis, released Thursday by consulting firm Avalere, examines the effect of a drug pricing negotiation framework that was included in a roughly $2 trillion package that passed the House on Friday.
The legislation would enable the Department of Health and Human Services to negotiate prices on 10 select products on Parts B and D in addition to all insulin products.
However, Avalere found that the negotiation framework will result in cuts to reimbursements for providers for Medicare Part B drugs,...
Today's Sponsors
Today's Sponsor